Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

27 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Metastatic melanoma presenting with subacute sensory neuronopathy.
Holm-Yildiz S, Crone C, Borch TH, Jeppesen TD. Holm-Yildiz S, et al. Among authors: borch th. Muscle Nerve. 2021 Aug;64(2):E5-E6. doi: 10.1002/mus.27327. Epub 2021 May 30. Muscle Nerve. 2021. PMID: 34008186 No abstract available.
Clinical efficacy of T-cell therapy after short-term BRAF-inhibitor priming in patients with checkpoint inhibitor-resistant metastatic melanoma.
Borch TH, Harbst K, Rana AH, Andersen R, Martinenaite E, Kongsted P, Pedersen M, Nielsen M, Kjeldsen JW, Kverneland AH, Lauss M, Hölmich LR, Hendel H, Met Ö, Jönsson G, Donia M, Svane IM. Borch TH, et al. J Immunother Cancer. 2021 Jul;9(7):e002703. doi: 10.1136/jitc-2021-002703. J Immunother Cancer. 2021. PMID: 34210820 Free PMC article.
Long-Lasting Complete Responses in Patients with Metastatic Melanoma after Adoptive Cell Therapy with Tumor-Infiltrating Lymphocytes and an Attenuated IL2 Regimen.
Andersen R, Donia M, Ellebaek E, Borch TH, Kongsted P, Iversen TZ, Hölmich LR, Hendel HW, Met Ö, Andersen MH, Thor Straten P, Svane IM. Andersen R, et al. Among authors: borch th. Clin Cancer Res. 2016 Aug 1;22(15):3734-45. doi: 10.1158/1078-0432.CCR-15-1879. Epub 2016 Mar 22. Clin Cancer Res. 2016. PMID: 27006492
Cost-effectiveness of treating advanced melanoma with tumor-infiltrating lymphocytes based on an international randomized phase 3 clinical trial.
Ten Ham RMT, Rohaan MW, Jedema I, Kessels R, Stegeman W, Scheepmaker W, Nuijen B, Nijenhuis C, Lindenberg M, Borch TH, Monberg T, Donia M, Marie Svane I, van Harten W, Haanen J, Retel VP. Ten Ham RMT, et al. Among authors: borch th. J Immunother Cancer. 2024 Mar 26;12(3):e008372. doi: 10.1136/jitc-2023-008372. J Immunother Cancer. 2024. PMID: 38531663 Free PMC article. Clinical Trial.
Ex vivo modulation of intact tumor fragments with anti-PD-1 and anti-CTLA-4 influences the expansion and specificity of tumor-infiltrating lymphocytes.
Hulen TM, Friese C, Kristensen NP, Granhøj JS, Borch TH, Peeters MJW, Donia M, Andersen MH, Hadrup SR, Svane IM, Met Ö. Hulen TM, et al. Among authors: borch th. Front Immunol. 2023 Jun 8;14:1180997. doi: 10.3389/fimmu.2023.1180997. eCollection 2023. Front Immunol. 2023. PMID: 37359554 Free PMC article.
Molecular patterns of resistance to immune checkpoint blockade in melanoma.
Lauss M, Phung B, Borch TH, Harbst K, Kaminska K, Ebbesson A, Hedenfalk I, Yuan J, Nielsen K, Ingvar C, Carneiro A, Isaksson K, Pietras K, Svane IM, Donia M, Jönsson G. Lauss M, et al. Among authors: borch th. Nat Commun. 2024 Apr 9;15(1):3075. doi: 10.1038/s41467-024-47425-y. Nat Commun. 2024. PMID: 38594286 Free PMC article.
T cells isolated from patients with checkpoint inhibitor-resistant melanoma are functional and can mediate tumor regression.
Andersen R, Borch TH, Draghi A, Gokuldass A, Rana MAH, Pedersen M, Nielsen M, Kongsted P, Kjeldsen JW, Westergaard MCW, Radic HD, Chamberlain CA, Hölmich LR, Hendel HW, Larsen MS, Met Ö, Svane IM, Donia M. Andersen R, et al. Among authors: borch th. Ann Oncol. 2018 Jul 1;29(7):1575-1581. doi: 10.1093/annonc/mdy139. Ann Oncol. 2018. PMID: 29688262 Free article. Clinical Trial.
27 results